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Abstract
Background: Many plants have been used in traditional medicine for their antibacterial, antifungal, antiprotozoal,
antiviral, antidiarrhoeal, analgesic, antimalarial, antioxidant, anti-inflammatory and anticancer activities.
In order to find novel antimicrobial and antiviral agents, the aim of the present study was the evaluation of the
antibacterial and antibiofilm susceptibility of Asphodelus microcarpus leaves extract. Moreover, the antiviral activity
and the phytochemical composition of the active extract were also determined.
Methods: Antimicrobial and antibiofilm activities of leaves ethanol extract of A. microcarpus were evaluated on 13
different microbial strains. We selected three different sets of microorganisms: (i) Gram-positive bacteria, (ii) Gram-
negative bacteria and (iii) yeasts. The potential antiviral activity of A. microcarpus leaves ethanol extract was evaluated
with a luciferase reporter gene assay in which the dsRNA-dependent RIG-I-mediated IFN-β activation was inducted or
inhibited by the Ebola virus VP35 protein. HPLC-DAD-MS was used to identify phenolic profile of the active extract.
Results: A. microcarpus leaves extract showed a potent inhibitory activity on Gram-positive bacteria while only a
reduced inhibition was observed on Gram-negative bacteria. No activity was detected against Yeasts. The extract
also showed an interesting antibiofilm motif on various bacterial strains (E. coli, S. aureus, S. haemolyticus and B. clausii).
Moreover, this extract significantly affected the Ebola virus VP35 inhibition of the viral RNA (vRNA) induced IFN response.
Conclusions: The overall results provide supportive data on the use of A. microcarpus as antimicrobial agent and a
potential source of anti-viral natural products.
Data collected set the bases for further studies for the identification of single active components and the development
of new pharmaceuticals.
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Background
The interest for plant extracts and derived compounds is
significantly increased over the last years, in the attempt
to identify new active substances with therapeutic prop-
erties [1, 2]. Plants are rich in a wide variety of secon-
dary metabolites such as tannins, terpenoids, alkaloids,
flavonoids, glycosides, which have been found to have in
vitro antimicrobial properties [3, 4]. In fact, they could
be a good alternative to synthetic chemical antimicrobial
agents and antibiotics, because of the serious side ef-
fects, antimicrobial resistance and the emergence of pre-
viously uncommon infections, which have been
increasing due to inappropriate or widespread overuse
of antimicrobials. There are several reports in the scien-
tific literature describing the antimicrobial properties of
crude extracts prepared from plants [5, 6] and recent
studies have been carried out on their anti-biofilm activ-
ities against different types of microorganisms [7]. Bio-
film is a complex matrix of microorganisms in which
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cells bind together and attach to biotic or abiotic surface
[8, 9]. It has been observed that biofilm formation is as-
sociated with many infectious diseases and is a major
concern for immunocompromised patients [10] because
it provides structural stability and protection to the bac-
teria, so that the entrapped bacteria become resistant
against extreme environmental conditions (i.e. pH,
temperature and presence of antibiotics).
Plant extracts show many biological activities [11–14]
and they stand as an infinite resource for drug develop-
ment, novel pharmacophores, and scaffolds for amplifica-
tion into efficacious drugs for a multitude of disease [1, 2].
A number of small molecules extracted from plants
are known for their antiviral effects, while no antiviral
drugs coming from plant constituents have been ap-
proved so far. For instance, flavonoids and anthraqui-
nones showed inhibitory activity against Influenza A
virus, Hepatitis C virus and HIV [15–20]. Defense mech-
anisms against invading pathogens are accurately con-
trolled by both innate and adaptive immunity. The
innate immune system, in particular, is crucial to initiate
these anti-pathogen immune activities of the host organ-
ism. The type I interferon (IFN) system is a major player
in antiviral defense against all kinds of viruses. Virus-
infected cells synthesize and secrete IFN that stimulates
susceptible cells to express potent antiviral mechanisms
that limit further viral growth and spread [21]. However,
highly pathogenic viruses such as Ebola virus (EBOV),
developed a number of strategies for counteracting in-
nate immune system responses [22, 23]. In particular,
the EBOV VP35 protein is essential for viral inhibition
of IFN production and, hence, it has been shown to be
an effective viral target [23, 24]. Within this context, one
approach to subvert this powerful immune response in-
hibition is to identify small molecules that potentiate or
activate the IFN signaling pathway, increasing IFN pro-
duction in response to viral infections to a level able to
overturn this inhibition.
Mediterranean area offers a great variety of endemic
plants in Europe and, due to its geographical isolation,
the island of Sardinia provides an even greater plant bio-
diversity, with significant variations in genetic and mo-
lecular characteristics as compared to plants grown in
other regions.
The primary benefit of plant-derived medicines is due
to their availability, fewer side effects and reduced tox-
icity. Ethnopharmacological studies have shown that a
number of them were used until less than 100 years ago
in folk medicine [25] and some of them were reported
to have therapeutic effects on inflammations and im-
mune system reinforcements [26].
Asphodelus microcarpus Salzm.et Vivi (Asphodelaceae)
is widely distributed over the coastal Mediterranean re-
gion and was traditionally used as an antimicrobial
agent [27]. In ethnobotanical literature, its use for otitis
and toothache in Algeria [28] and for lung diseases in
Sardinia [29] has been also reported. Several studies
were performed in order to verify its antimicrobial
activity [30–32]. Recently, antimicrobial activity of areal
part of A. microcarpus was evaluated on Propionibac-
terium acnes, implicated in the pathogenesis of acne
vulgaris [33], and on methicillin resistant Staphylococ-
cus aureus MRSA [34]. The methanolic extract of A.
microcarpus leaves demonstrated a higher anitimicro-
bial activity against Staphylococcus aureus and Candida
albicans [35].
A. microcarpus is traditionally used for the toothache
and this prompted us to investigate the anti-biofilm
activity and the potential antimicrobial activities of A.
microcarpus leaves extract against oral and environ-
mental bacteria frequently reported in dental unit water
line (Streptococcus spp., Staphylococcus spp., Escheri-
chia coli) [36].
Moreover, based on previous experiments described in
different publications [37, 38], potential antiviral activity
of A. microcarpus extract have been carried out.
Methods
Plant collection
Asphodelus microcarpus subsp. microcarpus Salzm. et
Viv. (syn. Asphodelus ramosus L. subsp. ramosus) leaves
were collected in southern Sardinia (Quartu Sant’Elena,
Cagliari, Italy). The GPS coordinates were 39° 22′41.5″
N and 09° 19′62.3″ E. The plant was identified by Dr.
Cecilia Loi, Department of Life and Environmental
Sciences, Section of Botany, University of Cagliari, Italy.
A voucher specimen (1405/16 Herbarium CAG) has
been deposited in the Museum Herbarium CAG (Life
and Environmental Sciences Department).
Plant materials were washed with deionized water, fro-
zen at −80 °C and then lyophilized. The dried plant was
stored at −80 °C until required.
Extraction procedure
The lyophilized plant materials (10 g) were extracted in
50 mL of ethanol for 24 h at room temperature under
continuous stirring. After filtration, ethanol extract was
diluted 10-fold with water and then lyophilized (Aspho-
delus Extract, AE). Dried powder was dissolved in 10%
DMSO for antimicrobial activity tests. For HPLC–
DAD–ESI/MS analyses, dried extract was dissolved in
1 mL of 0.1% formic acid: acetonitrile (70:30, v/v) and
filtered through a 0.22 μm disposable LC filter disk for
HPLC analysis.
Microbial strains
To evaluate the antimicrobial profile of AE, 13 different
microbial strains have been used. We selected three
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different sets of microorganisms: (i) Gram-positive bac-
teria, Staphylococcus aureus ATCC 6538 (American
Type Culture Collection), Staphylococcus haemoliticus
clinical isolate NC1, Streptococcus uberis human clinical
isolate NC 20, Streptococcus faecalis ATCC 29212,
Streptococcus mutans CIP103220 (Collection Institut
Pasteur), Streptococcus salivarius, strain k12 (from a
commercial product, Bactoblis®), Streptococcus pyogenes
human clinical isolate NC4, Streptococcus intermedius
DSMZ 20573 (German Collection of Microorganism and
cell culture), Bacillus clausii, (isolated from a commer-
cial product, Enterogermina®); (ii) Gram-negative bac-
teria, Escherichia coli ATCC 7075; (iii) Yeasts, Candida
albicans, Candida kruseii, Candida glabrata, human
oral clinical isolates, designed from BF1 to BF3 respect-
ively. E. coli, B. clausii, S. haemolyticus and S. aureus
were plated in Muller Hinton agar; Shaedler agar for
Streptococci and Sabouraud dextrose agar for fungi.
Prior to use, all the strains were stored in a tube con-
taining the proper medium broth with 20% of glycerol at
−80 °C. These microbial strains were used for an in vitro
susceptibility test: (a) the agar diffusion method, (b)
Minimal Inhibitory Concentration (MIC), (c) Minimum
Bactericidal Concentration (MBC), which were deter-
mined in accordance with the National Committee for
Clinical Laboratory Standards, NCCLS. In addition, the
Minimal Biofilm Inhibitory Concentration (MBIC) was
used to evaluate the AE antibiofilm activity [39].
Antimicrobial susceptibility testing
The Agar diffusion method was performed by using the
Kirby-Bauer (KB) procedure and used as preliminary
antimicrobial test to reveal the entire antimicrobial sus-
ceptibility profile for the examined AE. 1·107 cells/mL
were inoculated onto the surface of an agar plate con-
taining one of the subsequent bacterial growth agar me-
diums (Microbiol, Uta, Italy): (i) Muller-Hinton agar for
aerobic bacteria, (ii) Shaedler agar for Streptococcus
spp., (iii) Fungi on Sabouraud agar. This antimicrobial
activity test was performed following the NCCLS proto-
col by using a paper filter disc (Ø = 6 mm) impregnated
with AE work solution (1000 μg/mL). MIC and MBC
were performed only in susceptible microbial strains
with KB test and they were performed according to the
Micro-broth dilution method [40, 41] by using a ½ serial
dilution, from 500 to 3.9 μg/mL of the AE; the positive
controls were performed with a Chlorhexidine digluco-
nate solution (CHX), Sigma-Aldrich, ranged a concen-
tration from 500 to 0.48 μg/mL (Table 1). The cultures
were incubated in air at 37 °C for 24 h for the aerobic
strains and in 5% CO2 at 37 °C for the Streptococcal
species. For the biofilm evaluation, we used the proto-
col described by Montana University’s Center for Bio-
film Engineering [42]. A microplate containing serial
concentrations of the compound, inoculated with the
bacterial strains as previously described for MIC and
MBC evaluation, was incubated at 37 °C for 6 days to
permit the biofilm formation. The plate samples were
subsequently washed three times with Phosphate-
buffered saline GIBCO®PBS (ThermoFisher) to elimin-
ate planktonic cells; thus, the biofilm was stained with
100 μL of 0.1% w/v of crystal violet solution (Microbial,
Uta, Italy) for 10 min at 25 °C. After three washes with
PBS solution, 200 μL of 30% v/v acetic acid was added
in every well to solubilize the dye from the bacterial
biomass. The biofilm amount was measured with a
plate reader spectrophotometer (SLT-Spectra II, SLT
Instruments, Germany) at 450 nm. The experiment was
performed in triplicate and the MBIC represented the
lowest concentration showing a 450 nm absorbance
comparable with negative control, > 95% (sample with-
out bacteria).
Cell line and viral infection
A549 cells were propagated in DMEM (Gibco™) supple-
mented with 10% Fetal Bovine Serum (E.U.-approved,
South America Origin, Gibco™) and 1% penicillin/
streptomycin (Euroclone®). Cells were incubated at 37 °C
in humidified atmosphere of 5% CO2 and 95% air. For
production of vRNA, A549 cells were infected with
Influenza virus A/Puerto-Rico/8/34 (H1N1) strain (IAV/
PR/8/34) with a multiplicity of infection of 5. Five hours
after infection, total RNA was isolated using the RNeasy
Kit (Qiagen).
Table 1 Antibacterial profile of A. microcarpus leaves extract on
a set of different microorganisms
Strains Kirby-Bauer
Ø mm
aMIC
(μg/mL)
MBC
(μg/mL)
Gram-positive bacteria
Bacillus clausii 4 ± 1 250 >500
Staphylococcus aureus 10 ± 2 250 >500
Streptococcus salivarius -b -b -b
Streptococcus mutans -b -b -b
Staphylococcus haemolyticus 6 ± 1 250 >500
Streptococcus faecalis -b -b -b
Streptococcus intermedius -b -b -b
Streptococcus pyogenes -b -b -b
Streptococcus uberis -b -b -b
Gram-negative bacteria
Escherichia coli 4 ± 1 500 >500
aMIC values with CHX were ranged for all strains from 7.81 (S. aureus) to 3.9 (E.
coli) μg/mL
b(−) strain that resulted no sensitive with preliminary KB antimicrobial test
Ø = 0 mm, conc. 1000 μg/mL
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Cytotoxicity assay
The effect of AE on A549 cells proliferation was deter-
mined in 96-well plates (Spectra Plate, PerkinElmer).
Cells were seeded at initial density of 105 cells/mL and
cultured in DMEM (Gibco™) supplemented with 10% Fetal
Bovine Serum (E.U.-approved, South America Origin,
Gibco™) and 1% penicillin/streptomycin (Euroclone®), in
the presence or absence of serial dilutions of extract
(ranging from 100 μg/mL to 0.03 μg/mL). Camptothecin
was used as positive control Table 2. Plates were incubated
for 72 h at 37 °C in humidified atmosphere of 5% CO2
and 95% air. Cell viability was determined adding Presto-
Blue™ Cell Viability Reagent (Invitrogen). Following 1 h in-
cubation at 37 °C, relative fluorescence was read with a
Victor3 (Perkin Elmer). The percentages of cell viability
were calculated on the amount of living cells in extract
treated cells relative to untreated control cells (defined as
100% viability). Cytotoxicity graph was then generated by
plotting percentage of cell viability versus concentration of
extract. The concentration required to reduce cell growth
by 50% (CC50) was calculated using regression analysis of
cytotoxicity curves.
Luciferase reporter gene assay for measuring IFN-β
induction
The luciferase reporter gene assay was performed as
previously described [37]. Briefly, A549 cells (5 × 104
per well) were transfected with T-Pro P-Fect Transfec-
tion Reagent (T-Pro Biotechnology, Twin Helix) and
with the construct pGL IFN-β luc. Twenty-four h after
transfection, cells were additionally transfected with
Influenza virus A/PR/8/34 (H1N1) and incubated for
further 6 h at 37 °C with 5% CO2 in presence or ab-
sence of the extract. Then, cells were harvested with a
Luciferase Harvesting Buffer (50 mM Na-MES pH 7.8,
50 mM TrisHCl pH 7.8, 1 mM dithiothreitol, 0.2% Tri-
ton X-100). The crude cell lysates were clarified by cen-
trifugation and 50 μL of cleared lysates were added to
50 μL of Luciferase Assay Buffer (125 mM Na-MES
pH 7.8, 125 mM Tris–HCl pH 7.8, 25 mM magnesium
acetate, 2.5 mg/mL ATP) in a white 96-well plate
(OptiPlate, PerkinElmer). Immediately after addition of
50 μL of 1 mM D-luciferin into each well, the lumi-
nescent signal was measured in Victor3 luminometer
(Perkin Elmer). The relative light units measured were
normalized as the fold activity of the unstimulated con-
trol. Each assay was carried out in triplicate.
EBOV VP35 luciferase reporter gene inhibition assay
The above described luciferase reporter gene assay was
also performed for evaluating the IFN-β induction inhib-
ition mediated by EBOV VP35 protein. When the
pcDNA3-ZEBOV-VP35 was used as control, it was co-
transfected with the pGL IFN-β luciferase plasmid.
Inhibition of luciferase expression was indicated as per-
centage of induced control. Each assay was carried out
in triplicate.
HPLC-DAD-ESI/MS analysis
The AE was analyzed as previously reported [43]. Briefly,
the solvents were: (A) 0.1% formic acid, and (B) aceto-
nitrile. The elution gradient established was isocratic
15% B for 5 min, 15–20% B over 5 min, 20–35% B over
10 min, 35–50% B over 10 min, 50–60% B over 2 min,
isocratic 60% B for 5 min and re-equilibration the col-
umn, using a flow rate of 0.5 mL/min. Double online de-
tection was carried out in the DAD using 280 nm and
370 nm as preferred wavelengths and in the MS oper-
ated in the negative ion mode. The phenolic compounds
present in the samples were identified according to their
UV and mass spectra and by comparison with commer-
cial standards, when available.
Data analysis
Data are expressed as mean ± SD from three independ-
ent experiments. The analysis average of the treatment
was determined using t-student (Prism 6 program), and
the data were compared using the p values: p < 0.05 was
considered statistically significant.
Results
Antimicrobial susceptibility testing and citotoxicity of A.
microcarpus extract
When tested on 13 different microorganisms, AE showed
an inhibitory effect on Gram-positive bacteria while
lower inhibition was observed on the Gram-negative
bacteria E. coli (Table 1). When tested for antibiofilm
activity, AE showed an interesting effect on various
bacterial strains (E. coli, S. aureus, S. haemolyticus and
B. clausii). The MBIC was shown to be, except for B.
clausii, 2 or 4 fold lower than the respective MIC value,
Fig. 1. This result suggests that AE is able to counteract
the biofilm formation by the probable presence of anti-
attachment or quorum quenching substances [44]. No
activity was detected against yeasts (data not shown).
To evaluate the AE effects on the EBOV VP35 inhib-
ition of the IFN activation, we first screened AE for
eukaryotic cellular toxicity in order to determine the
appropriate concentrations for the following luciferase
Table 2 Cell growth inhibition of A549 cell line by plant extract.
Data shown are the mean ± SD of three independent
experiments performed in duplicate samples
Extract/compound aCC50 (μg/mL)
AE >100
Camptothecin 0.54 ± 0.15
aExtract/compound concentration required to reduce cell growth by 50%
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reporter IFN-β gene assays. Total AE showed no cyto-
toxic effects on A549 cells with a CC50 > 100 μg/mL.
Camptothecin was used as positive control. Considering
these results, the initial concentration of 30 μg/mL was
chosen to investigate the effects of a possible increase of
the dsRNA RIG-I-mediated IFN-β induction.
Potential antiviral activity of A. microcarpus
EBOV VP35 is a validated drug target involved in several
crucial processes for a successful viral replication and
propagation. In order to study the AE capacity to poten-
tiate the dsRNA-dependent RIG-I-mediated IFN-β induc-
tion, the luciferase reporter gene assay and the VP35
inhibition assay previously described were performed [37].
Results showed that AE was capable to significantly
potentiate (p value <0.05) dsRNA-dependent RIG-I-
mediated the IFN-β production at the concentrations of
10 μg/mL and 3 μg/mL (Fig. 2). Noteworthy, AE did not
stimulate the innate antiviral response when tested in the
absence of a vRNA stimulus (data not shown).
Given the ability of increasing IFN production follow-
ing dsRNA stimulation shown by AE in the IFN-β in-
duction assay, we then investigated whether such
increase of IFN-induction was adequate to subvert the
blockade of the signaling cascade mediated by EBOV
VP35. For this reason, the same AE concentrations were
tested in dsRNA-dependent RIG-I-mediated IFN-β in-
duction system in the presence of EBOV VP35.
Results showed that AE significantly reverted the
EBOV VP35 inhibition of the vRNA induced IFN
response at concentrations of 3–0.1 μg/mL (3 μg/mL
p < 0.05, 1 and 0.3 μg/mL p < 0.05, 0.1 μg/mL
p < 0.001) (Fig. 3).
Characterization of phenolic compounds in A. microcarpus
leaves extract
The HPLC phenolic profile of A. microcarpus leaves
extract, recorded at wavelength, λ = 330 nm, is shown in
Fig. 4. Data on retention times, (tr), wavelengths of
maximum absorbance (λmax), pseudo-molecular ions
([M-H]−), diagnostic fragments and tentative identifica-
tion for each peak of the phenolic compounds detected are
listed in Table 3. Results showed a phenolic profile similar
to the previously described in A. microcarpus flowers [43]
but, in this case, the major peak 2 occurs with luteolin-6-
C-glucoside. Moreover, cichoric acid and cumaril exosa
malic acid were not present in flowers extract.
Discussion
Asphodelus microcarpus leaves showed the ability to in-
hibit some Gram-positive and, with lower potency,
Fig. 1 Minimal biofilm inhibitory concentration (MBIC) on four
bacterial strains resulted biofilm sensitive at A. microcarpus extract.
MBIC represent the lowest concentration showing a 450 nm absorbance
>95% comparable with negative control, sample without bacteria
(ABS, SD ±15%). The CHX showed a MBIC values ranged from
3.9 to 0.97 μg/mL
Fig. 2 A. microcarpus leaves extract effects on IFN-β induction. The AE was tested in a RIG-I-mediated IFN-β induction system with vRNA stimulation.
Results are shown in n-fold compared to unstimulated control (* p value <0.05)
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Gram-negative bacteria but displayed no activities
against Streptococci spp. and yeasts.
If we compare two Gram positive bacteria groups, our
data demonstrate that AE extract is more active with
aerobic strains (Staphylococcus) than with facultative
anaerobic strains (Streptococcus). Following previous
reports, these differences in sensitivity could be due
to different cytoplasmic cell membrane composition.
In fact, flavonoids are able to interfere with different
cell membrane compounds in lipid bilayers and they
may control the arrangement of membrane proteins
with the formation of functional complexes respon-
sible for cell signal transduction and the regulation of
the metabolism [45]. In this context by using luteolin,
different authors reported decreases in ATPase activ-
ity and in the production/secretion of α-toxin in
Staphylococcus aureus [46, 47].
The antimicrobial activity of ethanolic extract from A.
microcarpus tubers has been previously published [32].
Moreover, a previous study reported the antimicrobial
Fig. 3 A. microcarpus leaves extract effects on IFN-β induction inhibition of EBOV VP35. The extract was tested in RIG-I-mediated IFN-β induction
system in presence of EBOV VP35 inhibition. Results are shown as the percentage of IFN-β promoter induction (* p value <0.05, ** p value <0.01,
*** p value <0.001)
Fig. 4 HPLC chromatogram of A. microcarpus leaves recorded at 330 nm for phenolic compounds. Peak identification is given in Table 3
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activities of methanolic extract of A. microcarpus leaves
[35]. Our results indicated that ethanolic extract of A.
microcarpus exhibited a different antimicrobial activity
against E. coli, S. aureus and Candida albicans if com-
pared with previous report [35]. It is considered that
these differences depend on solvent material and extrac-
tion process used.
In the present study, MBIC test was carried out to
evaluate the possible effects of AE on biofilm-mediated
diseases: results showed an antibiofilm effect against
some pathogens (E. coli, S. aureus, S. haemolyticus and
B. clausii). Further studies are required to explain if the
AE acts against biofilm formation through the quorum-
sensing pathway or it acts as an anti-attachment agent.
The discovery of small molecules able to reinforce the
innate antiviral response when it is under viral attack is
a novel and powerful approach against the inhibitory
strategies carried out by highly pathogenic viruses such
as EBOV through its VP35 protein. For this purpose, we
tested A. microcarpus leaves extract to verify if it was
capable to modulate the dsRNA-dependent RIG-I-
mediated IFN-β induction. It is noteworthy that the AE
did not stimulate the innate antiviral response when
tested in the absence of a vRNA stimulus and showed
the ability to potentiate the viral-induced IFN-β
production. Significantly, AE showed to be able to sub-
vert VP35 effects at different effective concentrations
with an almost similar efficacy between 3 and 0.1 μg/mL
and a lower effect at the higher dose of 10 μg/mL. It is
worth of note that the window of AE efficacy in sub-
verting VP35 inhibition of the IFN production is not
completely overlapping with the AE dose–response
IFN production shown in Fig. 2. Even if the reason of
this is not clear at the moment, it is possible to
speculate that the AE interaction with the IFN pro-
duction pathways could be different in the presence
of the viral protein. Smaller AE concentrations could
be effective in reverting the VP35 inhibition but the
IFN production system used could not be sensitive
enough in the absence of VP35. The VP35 reverting
activity, along with the fact that A. microcarpus leaves
extract acts only under antiviral response induction,
makes this plant extract very attractive for the
development of an antiviral drug. Indeed, further
studies will be required to: i) identify the constituent
of the extract responsible for the antiviral activity and
ii) determine the extract’s mode of action that, pre-
sumably, interacts with one or more components of
the RIG-I-mediated IFN signaling pathway increasing
IFN production. In fact, as shown by HPLC-DAD-
ESI/MS analysis (Fig. 4), A. microcarpus extract is a
complex matrix of several molecules, that could pos-
sibly act together inducing IFN production interacting
with different cellular targets, as proposed for other
synthetic compounds [48]. It is important to note that
phenolic characterization of Asphodelus microcarpus
leaves showed high presence of luteolin derivatives.
These flavones were extracted from many plants and
several studies showed their anti-inflammatory, anti-
bacterial, antioxidant and anti-HIV activity and may
be involved in AE biological activity [49–51].
In addition, luteolin has been shown to inhibit the kin-
ase activity of TBK [52] a component of the RIG-I cas-
cade. Hence, it is possible that either luteolin and/or
luteolin-C-glucoside may modulate dsRNA-dependent
RIG-I-mediated IFN-β production. Further studies will
be needed to investigate these possibilities. Overall, add-
itional studies will be also needed to characterize extract
fractions in order to identify the individual molecules
with biological activity.
Conclusion
Nowadays, natural products appear to be an interesting
solution against the emergency of the antibacterial re-
sistance and immune-regulators. In this study, A. micro-
carpus extract has shown a useful antibiofilm effect that
could have a crucial role against biofilm-mediated dis-
eases. However, other studies will be needed to clarify
AE active component as well as the AE mechanism in
Table 3 Identification of polyphenolic compounds in A.
microcarpus leaves extract by HPLC-DAD- ESI/MS analysis
Peak Rt
(min)
λmax
(nm)
Molecular ion
[M-H]− (m/z)
MS2(m/z),
(%)
Tentative identification
1 8.1 326 353 191(100)
354(50)
5-O-caffeoylquinic acid
2 15.4 350 447 429(30)
357(94)
327(95)
447(100)
Luteolin −6-C- glucoside
3 19.3 350 489 429(11)
357(38)
327(91)
489(100)
Luteolin −6-C-
acetilglucoside
4 21.2 336 473 311(100)
341(27)
283(17)
413(12)
429(3)
473(93)
Cichoric acid
5 23.2 332 623 623(100)
447(58)
429(38)
309(26)
417(24)
327(18)
Luteolin-C-glucoside
6 25.1 332 441 441(100)
213(48)
153(9)
195(8)
399(4)
Cumaril exosa malic acid
7 27 336 285 285(100) Luteolin
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the biofilm formation and to verify if others bacteria are
sensitive to AE.
Finally, given that EBOV VP35 is a paradigm protein
for potent viral IFN-suppression, the present study rep-
resents an interesting starting point for further studies
that should focus on: i) the study of the mechanism of
action of A. microcarpus extract and its constituents in
the dsRNA-dependent RIG-I-mediated IFN signaling
pathway, in order to potentiate the innate immune re-
sponse; ii) the design and synthesis of molecules as se-
lective inhibitors/revertant of EBOV VP35 inhibition of
IFN production. In the need for new available antiviral
therapeutics of natural origin, A. microcarpus appears to
be a promising starting point for the development of
molecules with broad antiviral activity.
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